Skip to main content
Top
Published in: Radiation Oncology 1/2018

Open Access 01-12-2018 | Research

Impact of 68Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology - a patterns of failure analysis in patients with primary diagnosis of prostate cancer

Authors: K. Schiller, M. Devecka, T. Maurer, M. Eiber, J. Gschwend, M. Schwaiger, S. E. Combs, G. Habl

Published in: Radiation Oncology | Issue 1/2018

Login to get access

Abstract

Background

68Ga-PSMA-PET-imaging has proven to be a highly sensitive and specific diagnostic element for patients with prostate cancer (PC). Does the standard clinical target volume (CTV) cover the majority of 68Ga-PSMA-PET detected lymph nodes (LNs) in a primary setting?

Methods

25 out of 159 patients with primary PC who underwent 68Ga-PSMA-PET-imaging were analyzed in the process of this study. These 25 high-risk patients had a total of 126 LNs with positive 68Ga-PSMA-ligand uptake. A standard CTV according to the ‘Radiation Therapy Oncology Group’ consensus was delineated and LNs were judged whether they were in- or outside of this target volume. With a Pearson correlation we additionally evaluated whether the Gleason score, the prostate-specific antigen (PSA) value or the risk according to the Roach formula correlate with a higher chance of LNs being outside of the CTV in uncommon LN locations.

Results

81 (64.3%) of 126 LNs were covered by the CTV with a complete coverage of all positive LNs inside the respective radiation volume in 11 of 25 patients (44%). LNs that were not covered by the CTV included (para-aortic,) common-iliac, pre-sacral, obturatoric, para-rectal, para-vesical and pre-acetabular locations. In a statistical analysis neither the Gleason score, nor the PSA value, nor the calculated risk with the Roach formula correlated with LNs being inside or outside of the CTV in this patient group.

Conclusion

68Ga-PSMA-PET-imaging proves to be a valuable asset for patients and physicians for primary diagnosis and treatment planning. In our study, trusting the RTOG consensus for CTV delineation would have led to up to 35.7% of all LNs not to be included in the clinical radiation volume, which might have resulted in insufficient radiation dose coverage.
Literature
1.
go back to reference Roach M 3rd, Marquez C, Yuo HS, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994;28:33–7.CrossRefPubMed Roach M 3rd, Marquez C, Yuo HS, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 1994;28:33–7.CrossRefPubMed
2.
go back to reference Partin AW, Yoo J, Carter HB, Pearson JD, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150(1):110–4. Partin AW, Yoo J, Carter HB, Pearson JD, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150(1):110–4.
3.
go back to reference Fendler WP, Schmidt DF, Wenter V, et al. 68Ga-PSMA PET/CT detects the location and extent of primary prostate cancer. J Nucl Med. 2016;57(11):1720–5. Epub 2016 Jun 3. Fendler WP, Schmidt DF, Wenter V, et al. 68Ga-PSMA PET/CT detects the location and extent of primary prostate cancer. J Nucl Med. 2016;57(11):1720–5. Epub 2016 Jun 3.
5.
go back to reference Rauscher I, Maurer T, Beer AJ, et al. Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med. 2016;57(11):1713–9. Epub 2016 Jun 3. Rauscher I, Maurer T, Beer AJ, et al. Value of 68Ga-PSMA HBED-CC PET for the assessment of lymph node metastases in prostate cancer patients with biochemical recurrence: comparison with histopathology after salvage lymphadenectomy. J Nucl Med. 2016;57(11):1713–9. Epub 2016 Jun 3.
6.
go back to reference Perera M, Papa N, Christidis D, et al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016;70(6):926–37. https://doi.org/10.1016/j.eururo.2016.06.021. Epub 2016 Jun 28. Perera M, Papa N, Christidis D, et al. Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2016;70(6):926–37. https://​doi.​org/​10.​1016/​j.​eururo.​2016.​06.​021. Epub 2016 Jun 28.
9.
11.
go back to reference D'Amico AV, Whittington R, Schultz D, Malkowicz SB, Tomaszewski JE, Wein A. - Outcome based staging for clinically localized adenocarcinoma of the prostate. J Urol. 1997;158(4):1422–6. D'Amico AV, Whittington R, Schultz D, Malkowicz SB, Tomaszewski JE, Wein A. - Outcome based staging for clinically localized adenocarcinoma of the prostate. J Urol. 1997;158(4):1422–6.
14.
go back to reference Eder M, Schafer M, Bauder-Wust U, Hull W-E, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23(4):688–97. https://doi.org/10.1021/bc200279b. Epub 2012 Mar 13. Eder M, Schafer M, Bauder-Wust U, Hull W-E, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23(4):688–97. https://​doi.​org/​10.​1021/​bc200279b. Epub 2012 Mar 13.
17.
go back to reference Schiller K, Sauter K, Dewes S, et al. Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after 68Ga-PSMA-PET imaging. Eur, J. Nucl Med Mol Imaging. 2017;44(10):1656–62. https://doi.org/10.1007/s00259-017-3746-9. Epub 2017 Jun 23 Schiller K, Sauter K, Dewes S, et al. Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after 68Ga-PSMA-PET imaging. Eur, J. Nucl Med Mol Imaging. 2017;44(10):1656–62. https://​doi.​org/​10.​1007/​s00259-017-3746-9. Epub 2017 Jun 23
Metadata
Title
Impact of 68Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology - a patterns of failure analysis in patients with primary diagnosis of prostate cancer
Authors
K. Schiller
M. Devecka
T. Maurer
M. Eiber
J. Gschwend
M. Schwaiger
S. E. Combs
G. Habl
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2018
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-018-0977-2

Other articles of this Issue 1/2018

Radiation Oncology 1/2018 Go to the issue